セフロキシム市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、グレード別、最終用途別、地域別、競合市場別、2020-2030年

セフロキシムの世界市場規模は、2024年に5億3,088万米ドルとなり、2030年には8億4,401万米ドルに達すると予測され、予測期間中に5.10%の複合年間成長率（CAGR）で成長すると予測されています。

同市場は、主にセフロキシムの幅広い抗菌特性と、呼吸器感染症や尿路感染症に対する効果的な治療に対するニーズの高まりによって、緩やかながらも一貫した成長を遂げています。

第二世代セファロスポリン系抗生物質であるセフロキシムは、グラム陽性菌とグラム陰性菌の両方に対して有効であるため、広く処方されています。気管支炎、副鼻腔炎、肺炎、中耳炎、各種皮膚感染症などの治療によく使用され、世界の抗菌薬治療において重要な役割を果たしています。

市場開拓は、特にヘルスケア・インフラが急速に変貌しつつある新興国市場における感染症罹患率の増加によってさらに促進されます。

主な市場促進要因

世界のヘルスケアセクターの拡大

主な市場課題

抗生物質耐性の増加

主な市場動向

細菌感染の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のセフロキシム市場に与える影響

第5章 世界のセフロキシム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 販売チャネル別（直接、間接）
  • グレード別（アキセチル、ナトリウム）
  • 用途別（気管支炎、淋病、ライム病、皮膚感染症、耳の感染症、咽喉感染症、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のセフロキシム市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のセフロキシム市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のセフロキシム市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のセフロキシム市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのセフロキシム市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 世界のセフロキシム市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Anhui BBAC Likang Pharmaceutical Co., Ltd.
• Zhuhai United Laboratories Co.
• Nectar Lifesciences Ltd.
• Dhanuka Laboratories Pvt Ltd
• Aurobindo Pharma Limited
• Covalent laboratories private limited
• Orchid Pharma
• Akums drugs & pharmaceuticals ltd
• Lupin Limited
• Hetero Labs Ltd

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Cefuroxime market was valued at USD 530.88 million in 2024 and is projected to reach USD 844.01 million by 2030, growing at a compound annual growth rate (CAGR) of 5.10% during the forecast period. The market is witnessing moderate yet consistent growth, primarily driven by Cefuroxime's broad-spectrum antibacterial properties and the rising need for effective treatments for respiratory and urinary tract infections.

As a second-generation cephalosporin antibiotic, Cefuroxime is widely prescribed due to its efficacy against both Gram-positive and Gram-negative bacteria. It is commonly utilized in the treatment of conditions such as bronchitis, sinusitis, pneumonia, otitis media, and various skin infections, thereby playing a vital role in global antimicrobial therapy.

Market growth is further fueled by the increasing incidence of infectious diseases, particularly in developing regions where healthcare infrastructure is undergoing rapid transformation.

Key Market Drivers

Expansion of the Global Healthcare Sector

The ongoing growth of the global healthcare industry significantly contributes to the Cefuroxime market's expansion. The hospital segment alone accounted for approximately 40% of the global healthcare market in 2022, with a value exceeding USD 3.9 trillion. This figure is expected to rise to 44% by 2029, reaching a projected market size of USD 5.19 trillion. As hospitals increasingly become central to healthcare delivery, the demand for broad-spectrum antibiotics such as Cefuroxime continues to grow in tandem with healthcare infrastructure improvements, enhanced access to medical services, and evolving treatment protocols.

Cefuroxime is widely utilized in the management of a broad range of bacterial infections, including respiratory tract infections, skin infections, urinary tract infections, and for surgical prophylaxis. As such, it remains an indispensable part of modern antimicrobial therapy.

Key Market Challenges

Rising Antibiotic Resistance

One of the most significant challenges facing the global Cefuroxime market is the increasing prevalence of antibiotic resistance, which is undermining the effectiveness of many broad-spectrum antibiotics, including second-generation cephalosporins. As bacterial strains develop mechanisms to resist antibiotic treatment, the therapeutic reliability of Cefuroxime is being compromised in certain indications.

This trend has led to a more cautious approach to antibiotic prescribing, in alignment with international antimicrobial stewardship efforts, potentially reducing prescription volumes in favor of newer, more targeted therapies. The emergence of multidrug-resistant bacteria presents a growing threat to public health, highlighting the need for innovation in antibiotic development. As an established molecule, Cefuroxime faces limitations in this evolving landscape, presenting both clinical and commercial challenges for pharmaceutical companies striving to balance responsible antibiotic use with sustained product viability.

Key Market Trends

Increasing Incidence of Bacterial Infections

The global rise in bacterial infections represents a key trend shaping the Cefuroxime market's growth trajectory. Bacterial infections are responsible for approximately 7.7 million deaths annually, accounting for one in every eight fatalities and ranking as the second leading cause of death worldwide. Alarmingly, nearly 5 million of these deaths are linked to antibiotic-resistant bacterial strains, highlighting the critical threat posed by antimicrobial resistance.

This escalating public health issue has driven heightened demand for broad-spectrum antibiotics like Cefuroxime, particularly in healthcare settings managing high incidences of respiratory, urinary tract, and skin and soft tissue infections. As a result, Cefuroxime continues to play a vital role in both inpatient and outpatient antimicrobial treatment strategies.

Key Market Players

• Anhui BBAC Likang Pharmaceutical Co., Ltd.
• Zhuhai United Laboratories Co.
• Nectar Lifesciences Ltd.
• Dhanuka Laboratories Pvt Ltd
• Aurobindo Pharma Limited
• Covalent laboratories private limited
• Orchid Pharma
• Akums drugs & pharmaceuticals ltd
• Lupin Limited
• Hetero Labs Ltd

Report Scope

In this report, the Global Cefuroxime Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefuroxime Market, By Sales Channel:

• Direct
• Indirect

Cefuroxime Market, By Grade:

• Axetil
• Sodium

Cefuroxime Market, By End Use:

• Bronchitis
• Gonorrhea
• Lyme Disease
• Skin Infection
• Ear Infection
• Throat Infection
• Others

Cefuroxime Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefuroxime Market.

Available Customizations:

Global Cefuroxime Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefuroxime Market

5. Global Cefuroxime Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By Grade (Axetil, Sodium)
  • 5.2.3. By End Use (Bronchitis, Gonorrhea, Lyme Disease, Skin Infection, Ear Infection, Throat Infection, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Cefuroxime Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By Grade
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cefuroxime Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By Grade
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Cefuroxime Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By Grade
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Cefuroxime Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By Grade
      • 6.3.3.2.3. By End Use

7. Europe Cefuroxime Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By Grade
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cefuroxime Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By Grade
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Cefuroxime Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By Grade
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Cefuroxime Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By Grade
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Cefuroxime Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By Grade
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Cefuroxime Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By Grade
      • 7.3.5.2.3. By End Use

8. Asia Pacific Cefuroxime Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By Grade
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cefuroxime Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By Grade
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Cefuroxime Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By Grade
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Cefuroxime Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By Grade
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Cefuroxime Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By Grade
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Cefuroxime Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By Grade
      • 8.3.5.2.3. By End Use

9. South America Cefuroxime Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By Grade
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cefuroxime Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By Grade
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Cefuroxime Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By Grade
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Cefuroxime Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By Grade
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Cefuroxime Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By Grade
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cefuroxime Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By Grade
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Cefuroxime Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By Grade
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Cefuroxime Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By Grade
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cefuroxime Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zhuhai United Laboratories Co.
• 15.3. Nectar Lifesciences Ltd.
• 15.4. Dhanuka Laboratories Pvt Ltd
• 15.5. Aurobindo Pharma Limited
• 15.6. Covalent laboratories private limited
• 15.7. Orchid Pharma
• 15.8. Akums drugs & pharmaceuticals ltd
• 15.9. Lupin Limited
• 15.10. Hetero Labs Ltd

16. Strategic Recommendations

17. About Us & Disclaimer